Sun Pharmaceutical Industries has entered into a collaboration with China Medical System Holdings (CMS) to develop and commercialize seven undisclosed generic products in mainland China. The agreement with the Chinese sales and marketing specialist builds on deals announced in late June this year whereby the Indian firm exclusively licensed to CMS two speciality products, the novel psoriasis treatment Ilumya (tildrakizumab) and Cequa (cyclosporine A) 0.09% eye drops, for marketing in Greater China.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?